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Abstract
Background: Mesenchymal stem cells (MSC) have gained credibility as a therapeutic tool partly due to their
potential to secrete factors such as cytokines and chemokines. Recently, exosomes, which mediate intercellular
communication by delivering biomolecules such as mRNA and miRNA into recipient cells, have gained attention as
a new and valuable therapeutic strategy in regenerative medicine. However, the potential role of exosomes
secreted by adipose-derived mesenchymal stem cells (adMSC-Exos) in collagen metabolism is not well understood.
The purpose of this study was to evaluate the effects of adMSC-Exos on collagen metabolism in cultured fibroblasts
from women with stress urinary incontinence (SUI).
Methods: Periurethral vaginal wall tissues of postmenopausal women with or without SUI were collected during
transvaginal surgical procedures. Primary fibroblasts were cultured from periurethral vaginal wall tissues, and the
levels of type I collagen mRNA and protein were examined by qRT-PCR and western blotting. MSC were isolated
from human adipose tissue by enzymatic digestion. Exosomes were prepared by ultracentrifugation of adMSC-
conditioned medium (adMSC-CM) and were confirmed by transmission electron microscopy and western blot
analyses. The effects of adMSC-CM and adMSC-Exos were assessed using qRT-PCR and western blotting.
Results: The type I collagen content was significantly decreased in periurethral vaginal wall tissues and cultured
vaginal fibroblasts from women with SUI. adMSC-CM increased the expression of the col1a1 gene in vaginal
fibroblasts from women with SUI. adMSC-Exos could be successfully isolated from adMSC-CM and could be
transferred to fibroblasts efficiently. adMSC-Exos increased the expression of col1a1 in vaginal fibroblasts from
women with SUI, and when the fibroblasts were treated with adMSC-Exos, the expression levels of TIMP-1 and
TIMP-3 in fibroblasts were upregulated, with significant downregulation of MMP-1 and MMP-2 expression levels.
Conclusions: adMSC-Exos increased type I collagen contents by increasing collagen synthesis and decreasing
collagen degradation in vaginal fibroblasts from women with SUI. adMSC-Exos may be a novel therapeutic
approach for treating SUI.
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Background
Stress urinary incontinence (SUI), the most common
form of incontinence, is defined as involuntary leakage
of urine with effort or exertion, such as coughing or
sneezing [1]. SUI is a major health problem affecting a
large number of women of reproductive and menopausal
ages and imposes a significant financial burden on health
systems worldwide [2, 3]. The underlying pathology and
cause of SUI remain unknown, but many studies suggest
that the development of SUI in women is accompanied
by fibroblast dysfunction and reduced collagen [4–8].
Surgical treatment is the current gold standard therapy
for SUI, and short-term success has been achieved with
injectable bulking agents [9, 10]. However, complications
and poor long-term efficacy cause patients to seek alter-
native treatments, especially those that may provide
safer and longer-lasting outcomes for SUI [11–13].
Recently, stem cell therapy has been extensively investi-
gated at the experimental level and in a variety of clinical
applications [14, 15]. Given its ability to induce tissue
regeneration, stem cell-based treatment represents a
promising strategy to overcome the limitations of current
treatments for SUI.
Mesenchymal stem cells (MSC) are currently the most
advanced and safe cell therapy tool for several diseases
because of their easy isolation, high expansion potential
resulting in an unlimited pool of transplantable cells,
low immunogenicity, amenability to ex vivo genetic
modification, and multipotency [16–19]. During the past
10 years, many pre-clinical and clinical studies on stem
cells for SUI treatment have been published. For example,
Zou et al. developed a tissue-engineered sling with bone
marrow-derived mesenchymal stem cells seeded in a de-
gradable silk scaffold and found that the tissue-engineered
sling showed convincing functional effects for the treat-
ment of stress urinary incontinence in a rat model [20].
Zhou et al. found that implantation of ADSCs via ureth-
ral/intravenous injection significantly decreased the ab-
normal voiding rate of an SUI rat model compared to the
control group [21]. Lee et al. reported that intrinsic
sphincter deficiency and mixed stress incontinency were
effectively improved in 10 of 39 women with various types
of stress urinary incontinence after transurethral umbilical
cord blood stem cell injection [22]. All the results above
indicate the regenerative potential of MSC for the treat-
ment of SUI, but our understanding of how MSC mediate
their effects on the continence mechanism is limited.
MSC are classically thought to exert a tissue repair
effect through their capacity for multilineage differenti-
ation and self-renewal. Indeed their regeneration and re-
pair effects have been mainly attributed to their secreted
factors rather than their multilineage differentiation cap-
acity [23, 24]. Exosomes which are defined as nanosized
membrane vesicles with a diameter of 30–100 nm have
been recently isolated from MSC-conditioned medium and
these stem cell-derived exosomes are suggested to be the
key intercellular communication mediators between MSC
and target cells and to be associated with numerous
physiological and pathological functions [25–28]. Here, to
better understand the exosome-mediated intercellular
communication between MSC and fibroblasts from
women with SUI relative to collagen metabolism we first
isolated and characterized human adipose-derived MSC
(adMSC-Exos). Then we investigated the roles of exosomes
secreted by adMSC-Exos in collagen metabolism. We ob-
served that adMSC-Exos can promote the proliferation of
fibroblasts. Furthermore advanced studies have shown that
adMSC-Exos promoted collagen synthesis and inhibited
collagen degradation by modulating the expression levels
of TIMP metallopeptidase inhibitor 1 (TIMP-1) matrix
metallopeptidase 1 (MMP-1) and type I collagen. To the
best of our knowledge, this is the first report to show that
adMSC-Exos can regulate collagen metabolism in fibro-
blasts from women with SUI. Because adMSC-Exos upreg-
ulate the concentration of type I collagen in fibroblasts
from women with SUI they may represent a potential
treatment candidate for SUI.
Methods
Tissue collection
Periurethral vaginal wall tissues were obtained from
SUI(+) (n = 12) and SUI(−) (n = 12) patients. A signed
informed consent form was obtained from all participat-
ing women. Women with a history of endometriosis,
gynecologic malignancies, connective tissue disorders,
prior pelvic surgery, and advanced pelvic organ prolapse
(higher than stage II on the Pelvic Organ Prolapse
Quantification system) were excluded. Approximately
1 cm2 of full-thickness periurethral vaginal wall was
excised 1 cm lateral to the urethrovesical junction from
women undergoing surgery for SUI. Biopsies (1 cm2)
of vaginal walls from a similar area were excised from
controls undergoing transvaginal gynecologic surgery.
Cell culture
We isolated fibroblasts from vaginal wall tissues and
cultured them as described previously [29]. The purity of
cultured fibroblasts was confirmed by immunofluores-
cence using mouse anti-alpha smooth muscle actin anti-
body monoclonal antibody (1:1000; Abcam, Cambridge,
MA, USA). Fibroblasts isolated from each patient’s vaginal
wall tissue were cultured in 6-well plates (BD Falcon,
Franklin Lakes,NJ,USA) in triplicate. Cells from passage 3
were used in the experiments.
Adipose tissue was obtained from human liposuction
aspirates with informed consent from the donors
(healthy women and SUI patients). Isolation of adMSC
was performed as previously reported [30]. Human
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adMSC were resuspended in the culture medium and
seeded at a density of 2 × 106 cells per dish (10 cm).
Cultures were maintained in a 37 °C incubator with 5%
CO2 and passaged with trypsin/ethylenediaminetetraace-
tic acid when the cells were 70% confluent.
Collagen synthesis assay
The percent of collagen synthesized (as a percent of total
protein) was determined [31]. The cells were washed
and incubated for 3 h at 37 °C with 2,3-3H-proline in
medium containing ascorbic acid (50 mg/mL). Cells and
media were collected, and the protein was precipitated
overnight with 20% trichloroacetic acid (TCA) at 4 °C.
The precipitate was collected by centrifugation at
3000 rpm for 10 min, and the obtained pellet was
washed three times with 5% TCA/0.01% proline. The
resulting pellet was dissolved in 0.2 M NaOH, and the
solution was titrated to a pH of 7.6 with 0.2 M HCl. This
solution was divided into two aliquots. One aliquot was
digested with 100 mL of collagenase (2 mg/mL;
Sigma-Aldrich, St Louis, MO, USA). The other aliquot
was incubated in the buffer (without collagenase) for 1 h
at 37 °C. Proteins were precipitated with 10% TCA and
0.5% tannic acid for 1 h on ice. The precipitate was
separated from the supernatant by centrifugation at
10,000 rpm for 5 min. The supernatants were retained,
and the pellets were dissolved in 0.2 M NaOH. Radio-
activity in the supernatants and the dissolved pellets was
determined by liquid scintillation counting. Synthesized
collagen was considered a collagenase releasable count
(supernatant of the collagenase-treated aliquot). Total
protein was the value of collagenase releasable counts
plus collagenase insensitive counts (pellet of the
collagenase-treated aliquot). A correction factor of 5.4
was applied to the collagenase insensitive counts to
correct for the relative abundance of proline and
hydroxyproline. Collagen synthesis is reported as a
percent of the total protein synthesized.
Western blot analysis
Sodium dodecyl sulfate (SDS) sample buffer (0.5 M
Tris-HCl, pH 6.8, 20% sucrose, 10% SDS, 1% bromophe-
nol blue) was added to the concentrated samples. After
equal amounts of protein (5 μg/lane) were separated on
4–20% gradient polyacrylamide gels (Bio-Rad, Hercules,
CA, USA) under nonreducing conditions, the gels were
blotted onto nitrocellulose membranes (Pierce, Wal-
tham, MA, USA) in an electrophoretic transfer cell
(Bio-Rad). Blots were blocked with 5% non-fat milk at
4 °C overnight and then probed with Anti-Collagen I
antibody (1:1000; Abcam, Cambridge, UK, ab23446),
anti-CD63 antibody (1:1000; Abcam, ab59479),
anti-Hsp70 antibody (1:1000; Abcam, ab2787) and
anti-CD81 antibody (1:1000; Abcam, ab59477) at room
temperature for 1 h. After three washes with PBS-T
(pH 7.4 and 0.1% Triton), the membrane was incu-
bated with sheep anti-mouse IgG conjugated to HRP
(NeoBioscience, Shenzhen, China) for 1 h at room
temperature, followed by three washes in PBS-T. The
band density was determined by Bio-Rad Quality One
Software.
Real-time RT–PCR
Total RNA was extracted with a Total RNA Isolation Kit
(Takara Bio, Shiga, Japan) according to the manufac-
turer’s instructions and quantified using spectrophotometry
(NANO drop 2000; Thermo Fisher Scientific, Waltham,
MA, USA). The primer sequences were: Col1a1, 5’-GAGG
GCCAA GACGAAGACATC-3′ (sense) and 5’-CAGATCA
CGTCATCGCACAAC-3′ (anti-sense); MMP-1, 5’-AAAA
TTACACGCCAGATTTGCC-3′ (sense) and 5′-GGT GT
GACATTACTCCAGA GTTG-3′ (anti-sense); MMP-2,
5’-GATACCCCTTTGA CGGTAAGGA-3′ (sense) and
5’-CCTTCTCCCAAGGTCCATAGC-3′ (anti-sense); MM
P-9, 5’-AGACCTGGGCAGATTCCAAAC-3′ (sense) and
5’-CGGCAAGTCTT CCGAGTAGT-3′ (anti-sense); TIM
P-1, 5’-AGAGTGTCTGCGGATACTTCC-3′ (sense) and
5’-CCAACAGTGTAGGTCTTGGTG-3′ (anti-sense); TIM
P-2, 5’-GCTG CGAGTGCAAGATCAC-3′ (sense) and
5’-TGGTGCCCGTTGATGTTCTTC-3′ (anti-sense); TIM
P-3, 5’-CATGTGCAGTACATCCATACGG-3′ (sense) and
5’-CATC ATAGACGCGACCTGTCA-3′ (anti-sense). The
relative expression of mRNAs was evaluated by the 2–ΔΔCt
method and normalized to the expression of GAPDH. The
cycling program involved preliminary denaturation at 95 °C
for 1 min, followed by 45 cycles of denaturation at 95 °Cfor
10 s, annealing at 62 °Cfor 25 s, and elongation at 62 °C for
20 s, followed by a final elongation step at 70 °C for 5 min.
Immunofluorescence staining
Fibroblasts were fixed at room temperature with 4% PFA
for 10 min. After permeabilization in 1% Triton X-100/
PBS for 15 min, nonspecific binding was blocked with
3% bovine serum albumin for 1 h at 37 °C. Then, fibro-
blasts were incubated in mouse anti-alpha smooth
muscle actin antibody monoclonal antibody (1:1000;
Abcam, ab119952) at the appropriate dilution at 4 °C
overnight. Secondary antibodies were used for 1 h at 37 °C
after washing with PBS. Hoechst counterstain was used
for visualization. Pictures were captured using an
Olympus inverted fluorescence microscope (Olympus,
Tokyo, Japan).
Flow cytometric analysis of cell immunophenotype
For immunophenotype analysis of adMSC, cells were tryp-
sinized and washed with 2 mL of phosphate-buffered saline
(PBS) containing 0.5% bovine serum albumin (BSA; Sigma)
per tube. Cells were counted and centrifuged at 1200 g for
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5 min. After discarding the supernatant, the cell pellet was
resuspended in 50 μL of PBS containing fluorescein iso-
thiocyanate (FITC)-labeled primary antibodies and
incubated at 4 °C for 30 min. FITC-labeled immuno-
globulin G1 (IgG1) of the same species and isotypes
was used as negative control. Finally, the cells were
washed twice with 2 mL of PBS containing 0.5% BSA and
resuspended in 0.5 mL of PBS for fluorescence-activated
cell sorting (FACS) analysis. The working concentra-
tions of the primary antibodies against human CD29
(eBioscience, San Diego, CA, USA; 11–0299-42), CD31
(eBioscience; 11–0319-42), CD34 (eBioscience; 11–
0349-42), CD44 (eBioscience; MA1–10228), CD105
(eBioscience; MA1–19594) and HLA-DR (eBioscience;
11–9956-42) were 10–20 ng/mL. Flow cytometric analysis
was performed with a flow cytometer BD Accuri™ C6 (BD
Biosciences, Franklin Lakes, NJ, United States). Data were
analyzed with CFlow Plus 1.0 (BD Biosciences).
Multilineage differentiation of adMSC
To identify the capacity for adMSC multilineage differenti-
ation, adMSCs were cultured under differentiation condi-
tions. For adipocyte differentiation, adMSCs were cultured
at 2–3 104/cm2 in DMEM with 10% FCS, 10− 6 M dexa-
methasone, 50 mg/mL ascorbic acid, and 100 mg/mL
1-methyl-3-isobutyl-xanthine (all from Sigma-Aldrich).
After 14 days, Oil Red O staining was performed to show
adipocyte differentiation. For osteoblast differentiation,
adMSCs were cultured at 104/cm2 in DMEM with 10%
FBS, 10 mM β-glycerophosphate, 10− 7 M dexamethasone,
and 0.2 mM ascorbic acid (all from Sigma-Aldrich). After
21 days, the cells were stained with ALP staining to reveal
osteogenic differentiation.
Exosome extraction
Exosome extraction was performed as previously de-
scribed [32]. AdMSC-Exos were generated from adMSCs
of healthy women, and SUI-Exos were generated from
adMSCs of SUI patients. Briefly, adMSCs were cultured
for 48 h before exosome isolation. Then, the medium was
harvested and centrifuged at 800 g for 5 min, followed by
2000 g for 10 min to remove the lifted cells. The superna-
tants were subjected to filtration on a 0.1-mm-pore polye-
thersulfone membrane filter (Corning, Corning, NY, USA)
to discard large vesicles and cell debris. Then, the mix-
tures were concentrated by a 100,000-Mw cutoff mem-
brane (Centricon® Plus-70, Merck Millipore, Burlington,
MA, USA). The volume of the supernatants was reduced
from approximately 250–500 mL to 30 mL. Then, the
supernatants were ultracentrifuged at 100,000 g for 1 h at
4 °C using a 70Ti rotor (Beckman Coulter, Brea, CA,
USA). Exosomes were then resuspended in 6 mL of PBS
and ultracentrifuged at 100,000 g for 1 h at 4 °C using a
100Ti rotor (Beckman Coulter).
Dil-labeled exosomes to fibroblasts
Purified adMSC-Exos were labeled with 1 μM of Dil
(Invitrogen, Waltham, MA, USA) as previously described
[33]. Pelleted exosomes were washed to remove unbound
Dil, resuspended in PBS/5% BSA, and then added to
fibroblast medium for 6 h. Fibroblasts were then
washed in PBS, fixed in 4% paraformaldehyde, and
imaged by microscopy.
Transmission electron microscopy
Purified exosomes were fixed with 1% glutaraldehyde in
PBS (pH 7.4). After rinsing, a 20-μL drop of the suspen-
sion was loaded onto a formvar/carbon-coated grid nega-
tively stained with 3% (w/v) aqueous phosphotungstic acid
for 1 min for observation by transmission electron micros-
copy (Hitachi, Tokyo, Japan, SU-8010).
Statistical analysis
All values are shown as the mean ± s.d. Differences
between two groups were determined with the unpaired
Student’s t test. ANOVA was used for multiple compari-
sons. P < 0.05 was considered significant.
Results
Collagen concentration in periurethral vaginal wall tissues
and cultured vaginal fibroblasts from women with or
without SUI
To investigate collagen expression levels in periurethral
vaginal wall tissues of postmenopausal women with or
without SUI, vaginal wall tissues were collected from
women with SUI during transvaginal surgical procedures
(Table 1). The total collagen concentration in periure-
thral vaginal wall tissues from women with SUI was
significantly downregulated compared to that in the
tissues from women without SUI (P < 0.05; Fig. 1a).
qRT-PCR analysis showed that the expression levels of
Col1a1 were significantly reduced in the women with
Table 1 Case description
With SUI Without SUI P value
(n = 12) (n = 12)
Age, yrs 63.08 ± 5.93 62.50 ± 8.15 0.843
Parity, n 2.67 ± 0.89 2.50 ± 0.80 0.633
Mode of labor Vaginal Vaginal
Birth weight, g 3345.83 ± 542.49 3283.22 ± 518.45 0.776
BMI, kg/m2 31.07 ± 2.83 29.33 ± 3.60 0.201
Menopausal duration, yrs 8.42 ± 2.19 8.50 ± 2.39 0.930
The data of age, parity, birth weight, body mass index (BMI) and menopause
duration of 12 patients in each group were compared, and no differences
were detected
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SUI (P < 0.01; Fig. 1b). Western blotting also demon-
strated that type I collagen was significantly reduced in
the patients with SUI (Fig. 1c).
Collagen is mainly synthesized by fibroblasts in periur-
ethral vaginal wall tissue. To examine collagen metabol-
ism changes in fibroblasts from women with SUI,
fibroblasts were isolated from periurethral vaginal wall
tissues of women with SUI and from healthy women.
We found that cultured vaginal fibroblasts from the
women with SUI showed more elongation than those
from the healthy women (Fig. 1d). Immunostaining assay
identified the fibroblast marker ɑ-smooth muscle actin
(ɑ-SMA) in these fibroblasts as expected (Fig. 1e).
qRT-PCR analysis showed that the expression of Col1a1
was significantly reduced in the patients with SUI
(Fig. 1f ). Western blotting also demonstrated that type I
collagen was significantly reduced in the patients with
SUI (Fig. 1g). Furthermore, we found that fibroblasts
from the women with SUI exhibited significant de-
creases in the expression levels of TIMP-1, TIMP-2 and
Fig. 1 Collagen concentration in periurethral vaginal wall tissues and cultured vaginal fibroblasts from women with or without SUI. a Total
collagen concentration measured as micrograms of hydroxyproline per milligrams of wet weight from urogenital tissues of women with SUI and
in urologically healthy women. The results are the mean ± s.d. (n = 12 for each group). *P < 0.05. b The levels of Col1a1 in urogenital tissues of
women with SUI and in urologically healthy women were analysed by qRT-PCR. **P < 0.01. c The expression of type I collagen in urogenital
tissues was determined by a western blot assay. d The morphology of cultured vaginal fibroblasts in women with SUI (ii) and in urologically
healthy women (i). e ɑ-SMA protein expression by immunofluorescence staining (green). Original scale bars = 50 μm. f The levels of Col1a1 in
cultured vaginal fibroblasts from women with or without SUI were analyzed by qRT-PCR. The results are the mean ± s.d. (n = 3 for each group).
*P < 0.05. g The expression of type I collagen in cultured vaginal fibroblasts was determined by a western blot assay. h The levels of TIMP-1,
TIMP-2, TIMP-3, MMP-1, MMP-2, and MMP-9 in fibroblasts from women with or without SUI were analyzed by qRT-PCR. The results are the
mean ± s.d. (n = 3 for each group). CON control, MMP-1 matrix metallopeptidase 1, MMP-3 matrix metallopeptidase 3, MMP-9 matrix
metallopeptidase 9, SUI stress urinary incontinence, TIMP-1 TIMP metallopeptidase inhibitor 1, TIMP-2 TIMP metallopeptidase inhibitor 2, TIMP-3
TIMP metallopeptidase inhibitor 3
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TIMP-3, while the mRNA expression levels of MMP-1,
MMP-2, and MMP-9, which reportedly increase collagen
degradation in stress incontinence, were significantly in-
creased (Fig. 1h). Taken together, these data suggested
that the type I collagen content was significantly de-
creased in periurethral vaginal wall tissues and cultured
vaginal fibroblasts from the women with SUI.
Characterization of human adMSC
MSC were initially isolated from the bone marrow; how-
ever, the isolation of bone marrow MSC requires invasive
aspiration from a donor, significantly restricting its appli-
cation. Because adipose tissue is another rich source of
MSC (adMSC) and enables auto-grafting, adipose tissue
has recently become a popular source for MSC isolation.
In this study, to study the effects of MSC on the collagen
metabolism of fibroblasts, we isolated MSC from human
adipose tissues. We found that human adMSC have a
characteristic morphology of fibroblast-like cells (Fig. 2b).
They express high levels of CD29, CD44, and CD105, but
they are persistently negative for CD31, CD34, and
HLA-DR (Fig. 2a) as previously reported [30]. Under ap-
propriate culture conditions, adMSC can differentiate into
adipocytes and osteoblasts as demonstrated by Oil red O
staining and ALP staining, respectively (Fig. 2c, d).
adMSC-conditioned medium regulates type I collagen
metabolism in cultured vaginal fibroblasts from women
with SUI
To study the effect of adMSC on collagen metabolism,
fibroblasts from women with SUI were treated with
adMSC-conditioned medium for 48 h. qRT-PCR and west-
ern blotting analysis showed that the expression of Col1a1
in fibroblasts from the women with SUI was significantly
increased after treatment with adMSC-conditioned medium
(Fig. 3a, b). Furthermore, when the fibroblasts were treated
with adMSC-conditioned medium, we found that the
expression levels of TIMP-1 and TIMP-3 were significantly
Fig. 2 Characterization of human adMSC. a Immunophenotype of human adMSC. b The morphology of human adMSC was observed under light
microscopy. Original scale bars = 50 μm. c The differentiation capacity of human adMSC was demonstrated by Oil red O staining for adipocytes
(c) and ALP staining for osteoblasts (d). Original scale bars = 50 μm
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increased, while the mRNA expression levels of MMP-1 and
MMP-2, which reportedly decrease collagen degradation in
stress incontinence, were significantly decreased (Fig. 3c).
Therefore, our results indicated that adMSC-conditioned
medium regulated collagen metabolism by increasing colla-
gen synthesis and decreasing collagen degradation in vaginal
fibroblasts in women with SUI.
Isolation and characterization of adMSC-Exos
To study the roles of exosomes in collagen metabolism,
adMSC-Exos were first isolated and characterized as
previously described [33]. Transmission electron mi-
croscopy analysis showed that the exosomes purified
from the adMSC-conditioned medium were round
membrane-bound vesicles with a size ranging from 30
to 100 nm in diameter (Fig. 4a). Western blot demon-
strated that the exosome marker proteins CD63,
HSP70, and CD81 were present in adMSC-Exos as
expected (Fig. 4b). To further investigate whether the
adMSC-Exos could be transferred to fibroblasts,
adMSC-Exos were labeled with Dil dye and incubated
with fibroblasts from women with SUI in vitro. The
uptake was confirmed by fluorescence microscopy.
After 8 h, more than 90% of the fibroblasts were
Dil-positive; the Dil-labeled adMSC-Exos had been
taken up and were transferred to cytoplasm compart-
ments (Fig. 4c). These data suggested that adMSC-Exos
were successfully isolated and could be efficiently trans-
ferred to fibroblasts.
adMSC-Exos regulate type I collagen metabolism in
cultured vaginal fibroblasts from women with SUI
To examine the effects of adMSC-Exos on collagen me-
tabolism, fibroblasts from women with SUI were treated
with exosomes for 48 h. Our results showed that the
expression levels of col1a1 were increased in the fibro-
blasts incubated with adMSC-Exos compared to those of
the fibroblasts incubated with SUI-Exos (Fig. 5a, b).
Moreover, when the fibroblasts were treated with
adMSC-Exos, the expression levels of TIMP-1 and
TIMP-3 in the fibroblasts were upregulated, with
significant downregulation of MMP-1 and MMP-2
(Fig. 5c). Taken together, our observations suggested
that adMSC-Exos increased the type I collagen content by
increasing collagen synthesis and decreasing collagen
degradation in vaginal fibroblasts from women with SUI.
Discussion
Stress urinary incontinence (SUI), which is defined as
involuntary leakage of urine during an increase in ab-
dominal pressure, is a prevalent urological problem that
is most common in women, with an incidence of 18.9%
in those aged > 20 years in China [34]. The cause of
stress urinary incontinence is multifactorial. Previous
studies have reported a decreased collagen content and
altered morphologic features in the pelvic support
tissues of women with stress urinary incontinence [7, 8].
In the present study, we found that the expression of
type I collagen in periurethral vaginal wall tissues of
postmenopausal women with SUI was significantly
decreased compared to that in tissues from women with-
out SUI, which is consistent with the observations of
Chen et al., who demonstrated a 60% lower collagen
content in the vaginal wall tissues of women with SUI
compared to that in tissues from age-matched continent
women [35].
Mesenchymal stem cells (MSC), which have the cap-
acity for self-renewal and differentiation into chondro-
cytes, osteoblasts, and adipocytes, can be isolated and
easily expanded from tissues such as bone marrow,
Fig. 3 adMSC-conditioned medium regulates type I collagen metabolism in cultured vaginal fibroblasts from women with SUI. a Fibroblasts were
incubated with adMSC-conditioned medium for 48 h. The mRNA levels of col1a1 were evaluated by qRT-PCR. The results are the mean ± s.d.
(n = 3 for each group). **P < 0.01. b The expression of type I collagen was determined by a western blot assay. c The mRNA levels of TIMP-1,
TIMP-3, MMP-1, and MMP-2 were evaluated by qRT-PCR. The results are the mean ± s.d. (n = 3 for each group). adMSC-CM adipose-derived
mesenchymal stem cell-conditioned medium, MMP-1 matrix metallopeptidase 1, MMP-3 matrix metallopeptidase 3, TIMP-1 TIMP metallopeptidase
inhibitor 1, TIMP-2 TIMP metallopeptidase inhibitor 2
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adipose tissue, the umbilical cord, placenta, dental pulp
and others [36, 37]. Here, we isolated MSC from human
adipose tissues, adMSC, expressing cell surface markers
such as CD29, CD44, and CD105, without the expression
of other markers, including CD31, CD34, and HLA-DR
surface molecules, and showing differentiation potential
into osteocytes and adipocytes under in vitro conditions.
It has been increasingly observed in various fields of re-
generative medicine that transplanted MSC do not neces-
sarily engraft and differentiate at the site of injury [38].
Fig. 5 adMSC-Exos regulate type I collagen metabolism in cultured vaginal fibroblasts from women with SUI. Fibroblasts were incubated with
adMSC-Exos or SUI-Exos for 48 h. a The levels of Col1a1 in cultured vaginal fibroblasts from women with SUI were analyzed by qRT-PCR. The
results are the mean ± s.d. (n = 3 for each group). **P < 0.01. b The expression of type I collagen was determined by a western blot assay. c The
levels of TIMP-1, TIMP-3, MMP-1, and MMP-2 in fibroblasts from women with SUI were analyzed by qRT-PCR. The results are the mean ± s.d.
(n = 3 for each group). adMSC-Exos exosomes secreted by adipose-derived mesenchymal stem cells, MMP-1 matrix metallopeptidase 1, MMP-3
matrix metallopeptidase 3, SUI stress urinary incontinence, TIMP-1 TIMP metallopeptidase inhibitor 1, TIMP-2 TIMP metallopeptidase inhibitor 2
Fig. 4 Isolation and characterization of adMSC-Exos. a Electron micrograph of exosomes isolated from adMSC-conditioned medium. The
arrowheads indicate exosomes. Original scale bars = 0.5 μm. b Western blotting was performed with adMSC-Exos (Exos) or adMSC-conditioned
medium (Medium). CD63, HSP70 and CD81 expression levels in exosomes were detected. c Fibroblasts were incubated with Dil-labeled exosomes
(Dil-Exos; Dil is shown in red) or carrier control (CON), and nuclei were stained with Hoechst 33,342 (blue). Original scale bars = 50 μm
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Recent studies have shown that the key mechanism by
which MSC contribute to tissue repair and regeneration is
through their paracrine function [39, 40]. The present
study found that the proliferation and type I collagen con-
tents of fibroblasts from women with SUI increased after
the fibroblasts were treated with adMSC-conditioned
medium. Furthermore, we also found that under the influ-
ence of adMSC-conditioned medium, the expression
levels of TIMP-1 and TIMP-3 were upregulated and the
expression levels of MMP-1 and MMP-2 were downregu-
lated. These results demonstrate that adMSC-conditioned
medium regulated collagen metabolism in fibroblasts from
women with SUI by increasing collagen synthesis and
decreasing collagenolysis.
Recent studies have revealed that transplanted MSC
may secrete abundant particles documented as exo-
somes, which are suggested to be central mediators of
intercellular communication [41]. Since the first report
of MSC-derived exosomes, a growing number of studies
have explored their regenerative potential using different
in vitro and in vivo models, and Hu et al. found that
ASC-Exos could be taken up and internalized by fibro-
blasts to stimulate cell migration, proliferation and colla-
gen synthesis [42]. In the present study, we successfully
isolated and purified exosomes from human adMSC. In
addition to demonstrating that Dil-labeled exosomes
could be transferred to the cytoplasm of cultured fibro-
blasts from women with SUI, we further showed that
the levels of type I collagen in cultured fibroblasts were
significantly increased after the fibroblasts were treated
with adMSC-Exos. We also found that adMSC-Exos up-
regulated the expression levels of TIMP-1 and TIMP-3
and downregulated the expression levels of MMP-1 and
MMP-2. These results were consistent with those from
adMSC-conditional medium, suggesting that adMSC-Exos
play a crucial role in regulating collagen metabolism in
fibroblasts from women with SUI.
Conclusions
To our knowledge, this is the first study demonstrating
the modulation of collagen metabolism in fibroblasts from
women with SUI by adMSC-Exos. Because exosomes are
easier to preserve and transfer and have low immunogen-
icity, they are safe for therapeutic administration. There-
fore, the use of adMSC-Exos provides an efficient and safe
alternative to mesenchymal stem cell-based therapies in
the treatment of SUI in the future.
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